Upcoming market catalysts in Q1 2023

Upcoming catalysts for the first quarter of 2023 include approval decisions by the US FDA on lecanemab for Alzheimer disease, trofinetide for Rett syndrome and beremagene geperpavec for the treatment of dystrophic epidermolysis bullosa (DEB).

Competing Interests

The author declares no competing interests.

留言 (0)

沒有登入
gif